Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. monthly Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E16.08 EPS (ttm)5.65 Insider Own0.10% Shs Outstand1.48B Perf Week1.01%
Market Cap155.62B Forward P/E7.81 EPS next Y11.65 Insider Trans-2.05% Shs Float1.71B Perf Month11.03%
Income8.39B PEG1.57 EPS next Q2.15 Inst Own63.30% Short Float1.45% Perf Quarter-0.94%
Sales34.06B P/S4.57 EPS this Y42.30% Inst Trans1.61% Short Ratio1.86 Perf Half Y4.44%
Book/sh-5.01 P/B- EPS next Y13.22% ROA11.30% Target Price93.69 Perf Year18.42%
Cash/sh- P/C- EPS next 5Y10.25% ROE-103.70% 52W Range62.55 - 97.86 Perf YTD2.65%
Dividend4.72 P/FCF22.20 EPS past 5Y36.80% ROI21.20% 52W High-7.12% Beta0.80
Dividend %5.19% Quick Ratio3.00 Sales past 5Y10.80% Gross Margin77.10% 52W Low45.31% ATR2.57
Employees30000 Current Ratio3.10 Sales Q/Q10.10% Oper. Margin39.90% RSI (14)61.08 Volatility2.31% 3.10%
OptionableYes Debt/Eq- EPS Q/Q22.50% Profit Margin24.60% Rel Volume0.64 Prev Close91.04
ShortableYes LT Debt/Eq- EarningsMay 01 BMO Payout77.50% Avg Volume13.31M Price90.89
Recom2.30 SMA201.50% SMA509.79% SMA20011.00% Volume8,511,657 Change-0.16%
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Jun-03-20 11:50AM  
08:57AM  
08:00AM  
07:02AM  
Jun-02-20 05:45PM  
04:00PM  
03:28PM  
02:50PM  
02:20PM  
12:27PM  
11:43AM  
11:36AM  
11:22AM  
10:53AM  
10:36AM  
10:30AM  
09:16AM  
08:03AM  
04:12AM  
03:31AM  
Jun-01-20 03:28PM  
12:25PM  
11:46AM  
11:40AM  
10:03AM  
10:00AM  
08:30AM  
08:03AM  
01:00AM  
May-31-20 03:11PM  
11:30AM  
May-29-20 06:47PM  
04:13PM  
May-28-20 05:06PM  
09:10AM  
08:12AM  
May-27-20 05:48PM  
12:16PM  
10:50AM  
09:36AM  
08:51AM  
08:30AM  
May-26-20 11:28AM  
May-25-20 11:45AM  
May-24-20 07:11AM  
May-22-20 04:26PM  
01:36PM  
12:10PM  
11:37AM  
10:41AM  
08:50AM  
01:05AM  
May-21-20 03:48PM  
09:56AM  
May-20-20 09:23AM  
08:59AM  
08:59AM  
08:43AM  
07:35AM  
06:45AM  
06:42AM  
May-19-20 12:00PM  
11:30AM  
07:51AM  
May-18-20 11:50AM  
09:55AM  
May-15-20 01:21PM  
10:45AM  
08:30AM  
May-14-20 08:00AM  
06:27AM  
May-13-20 03:45PM  
12:03PM  
11:06AM  
11:00AM  
08:00AM  
07:02AM  
May-12-20 06:45PM  
02:05PM  
12:59PM  
12:10PM  
11:04AM  
08:44AM  
06:23AM  
May-11-20 05:41PM  
12:59PM  
10:43AM  
08:05AM  
06:38AM  
May-10-20 07:55AM  
May-09-20 08:00AM  
May-08-20 04:54PM  
04:15PM  
11:45AM  
09:53AM  
07:55AM  
05:17AM  
May-07-20 09:50PM  
08:21AM  
05:43AM  
AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Jeffrey RyanSVP, US Commercial OperationsMay 12Sale90.0023,0242,072,21152,760May 12 05:44 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMay 05Sale85.0019,4451,652,8250May 07 05:01 PM
Durkin Brian LVP, ControllerMar 30Buy69.0075051,75016,844Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 20Buy67.5080054,00016,094Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 18Buy68.182,200150,00515,294Mar 20 04:56 PM
RAPP EDWARD JDirectorMar 03Buy87.872,875252,6172,875Mar 04 05:14 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerSep 27Sale75.0215,5151,163,8730Oct 01 05:52 PM
Schumacher Laura JVice ChairmanSep 16Buy70.4225,0001,760,523164,838Sep 18 04:25 PM
Donoghoe NicholasSVP, Enterprise InnovationAug 29Buy66.197,525498,05713,090Aug 30 04:08 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsAug 16Buy64.4415,5521,002,16965,304Aug 20 04:16 PM
AUSTIN ROXANNE SDirectorAug 01Buy65.6625,0001,641,400117,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 31Buy66.0230,0001,980,69092,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 30Buy66.3510,000663,50062,114Jul 31 04:46 PM
Gosebruch Henry OEVP, Chief Strategy OfficerJul 29Buy67.2830,0002,018,38575,763Jul 31 04:46 PM
AUSTIN ROXANNE SDirectorJun 26Buy67.5011,500776,25052,114Jun 28 04:47 PM
CHASE WILLIAM JEVP, Finance & AdministrationJun 26Buy67.3030,4002,045,920169,552Jun 28 04:47 PM
RAPP EDWARD JDirectorJun 26Buy67.307,500504,75030,662Jun 28 04:48 PM